Imfinzi OverviewDurvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as a checkpoint inhibitor drug. Contents 1 Medical uses 2 Clinical trials 3 References 4 External links Medical uses The US Food and D...
Read more Imfinzi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Durvalumab
Recent Imfinzi Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 50mg/ml
NDC Database Records for Imfinzi: (2 results)Sorted by National Drug Code
- 0310-4500 Imfinzi 120 mg/2.4ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp
- 0310-4611 Imfinzi 500 mg/10ml Intravenous Injection, Solution by Astrazeneca Pharmaceuticals Lp